CRFA Awards 16 New Grants and Fellowships

April 8th 2025

Elevating the Quality of Cancer Care Via Cross-Department Collaboration

Palbociclib with endocrine therapy did not improve outcomes in HR-positive, HER2-negative breast cancer, but improved invasive DFS in lobular disease.

Experts from Sibley Memorial Hospital discuss how multidisciplinary work has enhanced outcomes such as survival and resource use at their institution.

Rachit Kumar, MD;Michael J. Pishvaian, MD, PhD;Nina D. Wagner-Johnston, MD;Valerie Lee, MD;Armine K. Smith, MD;Pouneh Razavi, MD;Curtiland Deville Jr., MD

ESMO Develops Molecular Tumor Boards Guidelines to Standardize Practice

Experts from Sibley Memorial Hospital discuss how multidisciplinary work has enhanced outcomes such as survival and resource use at their institution.

The ESMO Precision Oncology Working Group recommendations can serve as guidance to define standards for MTBs to integrate precision oncology into practice.

Adjuvant Therapy and Post-Surgical Management Options for Kidney Cancer

The ESMO Precision Oncology Working Group recommendations can serve as guidance to define standards for MTBs to integrate precision oncology into practice.

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD

April 1st 2025

Once-Weekly Doses of Carfilzomib Show Balanced Benefit in Real-World RRMM

A recent Oncology Decoded podcast focuses on adjuvant therapy like pembrolizumab and optimal post-surgical care for patients with kidney cancer.

Belzutifan Improves Disease-Specific Symptoms/QOL vs Everolimus in RCC

A real-world analysis showed that 56 mg/m2 of carfilzomib once weekly offered many benefits over 56 mg/m2 twice weekly and 70 mg/m2 once weekly in myeloma.

Time to deterioration in physical functioning and role functioning was similar among those receiving belzutifan vs everolimus for renal cell carcinoma.

April 6th 2025

PENELOPE-B Trial Shows Mixed Palbociclib Results in Breast Cancer Subtypes

Time to deterioration in physical functioning and role functioning was similar among those receiving belzutifan vs everolimus for renal cell carcinoma.

Related Content

April 8th 2025

Elevating the Quality of Cancer Care Via Cross-Department Collaboration

Palbociclib with endocrine therapy did not improve outcomes in HR-positive, HER2-negative breast cancer, but improved invasive DFS in lobular disease.

Rachit Kumar, MD;Michael J. Pishvaian, MD, PhD;Nina D. Wagner-Johnston, MD;Valerie Lee, MD;Armine K. Smith, MD;Pouneh Razavi, MD;Curtiland Deville Jr., MD

ESMO Develops Molecular Tumor Boards Guidelines to Standardize Practice

Experts from Sibley Memorial Hospital discuss how multidisciplinary work has enhanced outcomes such as survival and resource use at their institution.

Adjuvant Therapy and Post-Surgical Management Options for Kidney Cancer

The ESMO Precision Oncology Working Group recommendations can serve as guidance to define standards for MTBs to integrate precision oncology into practice.

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD

April 1st 2025

Once-Weekly Doses of Carfilzomib Show Balanced Benefit in Real-World RRMM

A recent Oncology Decoded podcast focuses on adjuvant therapy like pembrolizumab and optimal post-surgical care for patients with kidney cancer.

Belzutifan Improves Disease-Specific Symptoms/QOL vs Everolimus in RCC

A real-world analysis showed that 56 mg/m2 of carfilzomib once weekly offered many benefits over 56 mg/m2 twice weekly and 70 mg/m2 once weekly in myeloma.

April 6th 2025